Electrical stimulation of the vmPFC serves as a remote control to affect VTA activity and improve depressive-like behavior

Bruchim-Samuel, Merav; Lax, Elad; Gazit, Tomer; Friedman, Alexander; Ahdoot, Hadas; Bairachnaya, Maryia; Pinhasov, Albert; Yadid, Gal

doi:10.1016/j.expneurol.2016.05.016

Cited by 22 publications

(8 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies, in turn, can guide the development of new models that better reflect the human condition. Comorbidity analyses are also crucial for directing therapeutic approaches such as transcranial magnetic stimulation and DBS (79,(140)(141)(142). Information from clinical imaging analyses could also provide insight for translational research directed toward synaptic and cell type-specific mechanisms of chronic pain and comorbid disorders.…”

Section: Future Directionsmentioning

confidence: 99%

The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities

Serafini

Pryce

Zachariou

2020

Biological Psychiatry

157

121

View full text Add to dashboard Cite

Chronic pain is a complex neuropsychiatric disorder characterized by sensory, cognitive, and affective symptoms. Over the past 2 decades, researchers have made significant progress toward understanding the impact of mesolimbic dopamine circuitry in acute and chronic pain. These efforts have provided insights into the circuits and intracellular pathways in the brain reward center that are implicated in sensory and affective manifestations of chronic pain. Studies have also identified novel therapeutic targets as well as factors that affect treatment responsiveness. Dysregulation of dopamine function in the brain reward center may further promote comorbid mood disorders and vulnerability to addiction. This review discusses recent clinical and preclinical findings on the neuroanatomical and neurochemical adaptations triggered by prolonged pain states in the brain reward pathway. Furthermore, this discussion highlights evidence of mechanisms underlying comorbidities among pain, depression, and addiction.

show abstract

Section: Future Directionsmentioning

confidence: 99%

The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities

Serafini

Pryce

Zachariou

2020

Biological Psychiatry

157

121

View full text Add to dashboard Cite

show abstract

“…An 8-week escitalopram treatment was shown to reduce irregular high functional connectivity in the bilateral dorsal medial PFC in MDD patients (Lyttle et al 2015; Wang et al 2015a) and, in rats, a 2-week administration of a selective serotonin reuptake inhibitor (SSRI), fluvoxamine, restored dendritic length and spine densities but not cortical thickness after early-life stress exposure (Lyttle et al 2015). Furthermore, it appeared that both high- and low-frequency electrical ventromedial PFC stimulations in rat models of depression attenuated depressive-like behavior (Bruchim-Samuel et al 2016; Lim et al 2015). …”

Section: Brain Regions and Neurocircuits Involved In Depression: Neurmentioning

confidence: 99%

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

et al. 2018

View full text Add to dashboard Cite

Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.

show abstract

“…Preclinical studies also found that vmPFC stimulation normalizes the local field potential activity in ventral tegmental area (i.e. the regions within reward circuit and be able to release dopamine), while the abnormal dopamine release is an important factor leading to formation of addiction [20] . However, randomized controlled studies on the efficacy of rTMS targeting the vmPFC area were still limited (i.e.…”

Section: Introductionmentioning

confidence: 99%

The exploration of optimized protocol for repetitive transcranial magnetic stimulation in the treatment of methamphetamine use disorder: A randomized sham-controlled study

Chen

et al. 2020

EBioMedicine

View full text Add to dashboard Cite

Background The prefrontal-striatal circuit is a core circuit related to substance dependence. Previous studies have found that repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (DLPFC) (key region of executive network) had limited responses, while inhibiting hyperactivation of ventromedial prefrontal cortex (vmPFC) (key region of limbic network) may be another strategy. However, there is currently no comparison between these two treatment locations. Methods Seventy-four methamphetamine-dependent patients were randomly assigned to one of treatment groups with two-week treatment: (1) Group A: intermittent theta-burst stimulation (iTBS) targeting the left DLPFC; (2) Group B: continuous theta-burst stimulation (cTBS) targeting the left vmPFC; (3) Group C: a combination of treatment protocol of Group A and Group B; (4) Group D: sham theta-burst stimulation. The primary endpoint was the change of cue-induced craving. The trial was registered at ClinicalTrials.gov (NCT03736317). Findings The three real TBS groups had more craving decrease effect than the sham group ( p <0.01). The changes of craving were positively correlated with the improvement of anxiety and withdrawal symptom. With the highest respondence rate, group C also had shorter respondence time than Group A ( p = 0.03). Group C was effective in improve depression symptoms ( p = 0.04) and withdrawal symptom ( p = 0.02) compared with Group D. Besides, Group C was significant in improve sleep quality ( p = 0.04) compared with Group A. Baseline depression scores and spatial working memory were positively predicting the intervention response. Interpretation The rTMS paradigms involving vmPFC with cTBS are optimized protocols and well-tolerated for methamphetamine-dependent individuals, and they may have better efficacies compared with DLPFC iTBS. Emotion and cognitive function are rTMS treatment response predictors for methamphetamine-dependent patients. Funding This work was supported by the National Key R&D Program of China (2017YFC1310400), National Natural Science Foundation of China (81,771,436, 81,801,319, 81,601,164), Shanghai Municipal Health and Family Planning Commission (2017ZZ02021), Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ013), Qihang Project of Shanghai Mental Health Center (2019-QH-05), Shanghai Sailing Program (19YF1442100), Shanghai Key Laboratory of Psychotic Disorders (13DZ2260500), Program of Shanghai Academic Research Leader (17XD1403300), Shanghai Municipal Science and Technology Major Project (2018SHZDZX05), and Shanghai Clinical Research Center for Mental Health (19MC1911100).

show abstract

Electrical stimulation of the vmPFC serves as a remote control to affect VTA activity and improve depressive-like behavior

Cited by 22 publications

References 71 publications

The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities

The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

The exploration of optimized protocol for repetitive transcranial magnetic stimulation in the treatment of methamphetamine use disorder: A randomized sham-controlled study

Contact Info

Product

Resources

About